Mycala Partners with TV Berlin to Showcase Chinese Film and Culture
24.2.2023 23:00:00 EET | Business Wire | Press release
Chinese cinema made a splash at the 73rd Berlin International Film Festival this week, with over ten Chinese films selected for the competition and screening sections. These works showcased the creativity and perspectives of Chinese filmmakers across a wide range of subjects, marking a resounding return after the disruptions of the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005250/en/
Ms. Shi Yan, Founder & President of Mycala, walks the 73rd Berlinale’s red carpet (Photo: Business Wire)
To promote public interest in Chinese films, Mycala has partnered with TV Berlin to produce a special program (https://youtu.be/E0Sl3RJ4C1w) featuring interviews with the directors of three Chinese films competing or shown at this year's festival.
"By sharing outstanding Chinese films and the creative process behind them with a wider international audience, we hope to broaden understanding of Chinese culture and people’s life," said Shi Yan, Founder and President of Mycala. "The art of cinema creates bridges of communication with the audience as the language of the camera conveys emotion and awakens empathy."
The three films selected into this special program are Wu Lang’s “ Absence” from the Encounters section, “ Mad Fate” by Hong Kong director Soi Cheang screened in the Berlinale Special, and Zhang Dalei's “ All Tomorrow's Parties”, that competes in the Berlinale Shorts starring Zhou Xun and Wang Yibo.
In these interviews, the filmmakers discuss the creative process and emotional themes behind their works, personal experiences on their journeys through cinema, and thoughts on the future of the film industry.
Founded in Berlin in 2008, Mycala specializes in cross-border operations and distribution for high-end brands, representing over 60 international brands in the Asia market, focusing on China. Mycala is committed to the pursuit of fashion and high quality of life, creating value through cutting-edge ideas and technology. In recent years, the company has worked to promote cultural exchange between China and abroad, creating online and offline platforms for communication and interaction that have gained recognition both in China and overseas.
At this year's Berlinale, Shi Yan walked the red carpet as the only Chinese VIP invited by Armani Beauty, the principal partner of the festival.
"The art of cinema is an integral part of high-quality living and an important vehicle for cross-cultural understanding and communication," she said. "Supporting exchanges in the cultural field, including the film industry, is aligned with Mycala's vision to lead in fashion and help people pursue high-quality lives through new ideas, technology, and values."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005250/en/
Contact information
Shelly Wang
contact@panoramist-consulting.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 16:00:00 EEST | Press release
Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software. "Almost every organization we speak to is trying to get its data ready for AI, and most of them are realizing that the hard part is not the model, it is the da
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 16:00:00 EEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom